The expanded innovation center will enhance the company's research and development efforts to support customized product and bioprocess development, as well as cell and gene therapy reagent manufacturing to support customers' therapeutic products for personalized medicines.

The Bridgewater site now has nearly double the laboratory and support space. The center will house new bioprocessing products that minimize risk of contamination and variability for cell and gene therapy, monoclonal antibodies, and vaccines. Some of these products include high-purity products, single-use solutions, and small-volume current good manufacturing practice reagents in single-use bags.

For example, the recently launched JT Baker Bakerbond ProchievA recombinant protein A resin for purifying monoclonal antibodies was developed at the Bridgewater innovation center.

High-throughput analysis speeds downstream process development
Adding high-throughput analysis helped speed up downstream process development for drug candidates based on monoclonal antibodies, according to a case...

Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher...